197 related articles for article (PubMed ID: 20336787)
1. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis.
Mayo SC; Austin DF; Sheppard BC; Mori M; Shipley DK; Billingsley KG
Cancer; 2010 Jun; 116(12):2932-40. PubMed ID: 20336787
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).
Corsini MM; Miller RC; Haddock MG; Donohue JH; Farnell MB; Nagorney DM; Jatoi A; McWilliams RR; Kim GP; Bhatia S; Iott MJ; Gunderson LL
J Clin Oncol; 2008 Jul; 26(21):3511-6. PubMed ID: 18640932
[TBL] [Abstract][Full Text] [Related]
3. A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma.
McDade TP; Hill JS; Simons JP; Piperdi B; Ng SC; Zhou Z; Kadish SP; Fitzgerald TJ; Tseng JF
Cancer; 2010 Jul; 116(13):3257-66. PubMed ID: 20564625
[TBL] [Abstract][Full Text] [Related]
4. Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma.
Yang R; Cheung MC; Byrne MM; Jin X; Montero AJ; Jones C; Koniaris LG
Arch Surg; 2010 Jan; 145(1):49-56. PubMed ID: 20083754
[TBL] [Abstract][Full Text] [Related]
5. Adenocarcinoma of the head of the pancreas: effects of surgical and nonsurgical therapy on survival--a ten-year experience.
Carr JA; Ajlouni M; Wollner I; Wong D; Velanovich V
Am Surg; 1999 Dec; 65(12):1143-9. PubMed ID: 10597062
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
Schnelldorfer T; Ware AL; Sarr MG; Smyrk TC; Zhang L; Qin R; Gullerud RE; Donohue JH; Nagorney DM; Farnell MB
Ann Surg; 2008 Mar; 247(3):456-62. PubMed ID: 18376190
[TBL] [Abstract][Full Text] [Related]
7. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
Miller RC; Iott MJ; Corsini MM
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):364-8. PubMed ID: 19735864
[TBL] [Abstract][Full Text] [Related]
8. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.
Cleary SP; Gryfe R; Guindi M; Greig P; Smith L; Mackenzie R; Strasberg S; Hanna S; Taylor B; Langer B; Gallinger S
J Am Coll Surg; 2004 May; 198(5):722-31. PubMed ID: 15110805
[TBL] [Abstract][Full Text] [Related]
10. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.
Stessin AM; Meyer JE; Sherr DL
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1128-33. PubMed ID: 18538501
[TBL] [Abstract][Full Text] [Related]
12. Molecular metastases in stage I pancreatic cancer: improved survival with adjuvant chemoradiation.
Demeure MJ; Doffek KM; Komorowski RA; Redlich PN; Zhu YR; Erickson BA; Ritch PS; Pitt HA; Wilson SD
Surgery; 1998 Oct; 124(4):663-9. PubMed ID: 9780986
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.
Chao C; Hoffman JP; Ross EA; Torosian MH; Eisenberg BL
Am Surg; 2000 Apr; 66(4):378-85; discussion 386. PubMed ID: 10776876
[TBL] [Abstract][Full Text] [Related]
14. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma.
Pendurthi TK; Hoffman JP; Ross E; Johnson DE; Eisenberg BL
Am Surg; 1998 Jul; 64(7):686-92. PubMed ID: 9655283
[TBL] [Abstract][Full Text] [Related]
15. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
16. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.
Bilimoria KY; Bentrem DJ; Ko CY; Tomlinson JS; Stewart AK; Winchester DP; Talamonti MS
Cancer; 2007 Sep; 110(6):1227-34. PubMed ID: 17654662
[TBL] [Abstract][Full Text] [Related]
17. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
[TBL] [Abstract][Full Text] [Related]
19. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
Hallemeier CL; Botros M; Corsini MM; Haddock MG; Gunderson LL; Miller RC
Am J Clin Oncol; 2011 Dec; 34(6):567-72. PubMed ID: 21150564
[TBL] [Abstract][Full Text] [Related]
20. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
